Browse the evidence

Anti-Müllerian Hormone (AMH) testing can be used as an alternative to ultrasound for diagnosing PCOS in adults, offering a low-cost, convenient option without evidence of overdiagnosis.

If you are an adult being evaluated for PCOS, ask your doctor if Anti-Müllerian Hormone (AMH) blood testing is a suitable alternative to ultrasound. This may be a more convenient and cost-effective diagnostic option with strong supporting evidence.

Consumption of probiotic yoghurt containing specific strains (L. acidophilus La5 and B. lactis Bb12) improves glycemic control (fasting blood sugar, HbA1c) and lipid profiles in patients with Type 2 Diabetes.

If you have Type 2 Diabetes, incorporating 300g of probiotic yoghurt daily (specifically with L. acidophilus La5 and B. lactis Bb12) may help lower blood sugar and cholesterol levels. Consult your doctor before making dietary changes.

Higher TyG-BMI values are positively and linearly associated with increased risk of cardiovascular disease in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.

If you have metabolic risk factors or early kidney/heart issues, monitoring your Triglyceride-Glucose BMI (TyG-BMI) is a valuable tool for predicting heart disease risk. This index combines your body mass with blood sugar and fat levels to assess insulin resistance. Keeping this index low through lifestyle management (diet and exercise) is critical for preventing cardiovascular events, especially if you are over 45.

For very short bouts of physical activity (less than 1 minute), a minimum proportion of vigorous intensity (at least 12-15%) is required to significantly reduce the risk of Major Adverse Cardiovascular Events (MACE), though all-cause mortality benefits may appear at lower vigorous thresholds.

If you can only manage very short bursts of activity (under a minute), make sure they include some vigorous effort, like running up stairs quickly or walking very fast. This high-intensity component is crucial for protecting your heart when the duration is minimal.

Higher percentages of REM and deep sleep are associated with a reduced incidence of atrial fibrillation, while higher light sleep percentages are associated with increased odds of atrial fibrillation.

Prioritize sleep quality that promotes REM and deep sleep. While total duration is important, the composition of your sleep matters for heart health. Consistent sleep schedules and avoiding alcohol before bed may help increase deep and REM sleep, thereby reducing atrial fibrillation risk.

Average daily sleep duration exhibits a J-shaped association with hypertension, major depressive disorder, and generalized anxiety disorder, where both short (5h) and long (10h) durations increase risk compared to the median (6.8h).

Aim for approximately 7 hours of sleep per night. Both sleeping significantly less (5 hours) or significantly more (10 hours) is associated with higher risks of hypertension, depression, and anxiety. Use your wearable to track your average daily sleep duration and adjust your schedule to stay within the moderate range.

Semaglutide at its maximum tolerated dose (MTD) is associated with the highest odds of treatment discontinuation due to adverse events among all tested regimens, including tirzepatide MTD.

If you choose semaglutide at its maximum dose, be aware that you have the highest statistical risk of stopping the medication due to side effects compared to other options in this study. Monitor your tolerance closely and communicate with your provider immediately if side effects become unmanageable.

Tirzepatide demonstrates cardiovascular safety, with hazard ratios for major adverse cardiovascular events (MACE) remaining below 1.3 compared to pooled comparators, indicating no increased cardiovascular risk.

For patients with heart disease or high risk factors, Tirzepatide has been shown to be safe regarding cardiovascular events. It does not increase the risk of heart attack, stroke, or cardiovascular death compared to standard treatments. This makes it a viable option for those who need effective diabetes management without compromising heart health.

Resting metabolic rate (RMR) reduction following weight loss is driven primarily by the loss of adipose tissue mass and metabolic adaptations, rather than the loss of skeletal muscle mass.

You don't need to obsess over preserving every gram of muscle to stop your metabolism from slowing down. Research shows that losing fat mass itself, along with hormonal shifts (like lower leptin and thyroid hormones), is what actually drives your resting metabolic rate down after weight loss. This means metabolic adaptation is a natural response to losing fat, not just a failure to build muscle. To manage this, focus on sustainable, slower weight loss and personalized strategies that address these hormonal changes, rather than just trying to 'save' muscle.

Chronic low-grade inflammation, driven by obesity and ectopic lipid deposition, impairs insulin signaling and beta-cell function through pathways like NF-κB, JNK, and oxidative stress.

Inflammation is not just a symptom of diabetes; it is a cause. Excess fat, especially around organs (ectopic fat), triggers inflammation that blocks insulin from working and damages insulin-producing cells. Managing weight and diet reduces this inflammation.

GIP promotes lipogenesis (fat storage) in adipose tissue, while GLP-1 promotes lipolysis (fat breakdown) indirectly via sympathetic nervous system activation.

GIP helps store fat in adipose tissue, while GLP-1 helps break it down. Dual agonists balance these effects to improve overall metabolic health.

Menstrual cycle phase does not appreciably influence acute strength performance or chronic adaptations (strength/hypertrophy) to resistance exercise training in naturally cycling women.

Do not restrict your training volume, intensity, or frequency based on your menstrual cycle phase. The current scientific consensus indicates that hormonal fluctuations across the cycle do not significantly impact your ability to build strength or muscle. Focus on consistent, high-quality resistance training regardless of where you are in your cycle. If you experience menstrual symptoms that affect your well-being, adjust for comfort, not for perceived biological incapacity.

Systemic inflammation and HPA-axis dysregulation are biological mechanisms mediating the link between high body weight and psychological distress.

Understand that biological factors like inflammation and stress hormone dysregulation contribute to the link between obesity and depression. This is not just 'in your head' but has a physical basis.

GLP-1 receptor agonists (specifically liraglutide and dulaglutide) are associated with a statistically significant increase in the risk of overall thyroid disorders compared to placebo or other interventions, although they do not significantly increase the risk of specific conditions like thyroid cancer, hyperthyroidism, or hypothyroidism.

If you are taking a GLP-1 medication like liraglutide or dulaglutide, be aware that there is a slightly higher statistical risk of developing 'overall thyroid disorders' compared to those not taking the drug. However, this does not appear to increase your risk of thyroid cancer or major thyroid dysfunction. Standard monitoring is advised, but the fear of cancer based on animal studies is not supported by large human clinical trials.

Among specific GLP-1 receptor agonists, liraglutide and dulaglutide show a statistically significant increase in the risk of overall thyroid disorders, whereas semaglutide, lixisenatide, and exenatide do not show a significant effect.

Not all GLP-1 medications affect the thyroid equally. If you are concerned about thyroid health, liraglutide and dulaglutide have shown a statistically significant increase in overall thyroid disorders in large trials, whereas semaglutide, lixisenatide, and exenatide have not shown this significant risk. Discuss these differences with your provider when choosing a specific agent.

Tirzepatide requires GIP receptor (GIPR) activation to stimulate insulin secretion in human islets, as blocking GIPR consistently reduces this response.

Tirzepatide's effectiveness in lowering blood sugar relies on its ability to activate the GIP receptor, not just the GLP-1 receptor. In human tissue, blocking the GIP receptor stops tirzepatide from stimulating insulin, proving this second pathway is essential for its full benefit.

Tirzepatide stimulates glucagon secretion in human islets primarily through GIP receptor activation, which overrides the glucagon-suppressing effect of GLP-1 receptor activation.

Tirzepatide increases glucagon secretion via the GIP receptor, which might seem counterintuitive for a diabetes drug. However, this is a normal physiological response to nutrient sensing, and the drug's overall effect is still a significant reduction in blood glucose due to its powerful insulin-stimulating effects.

Tirzepatide stimulates insulin secretion in mouse islets predominantly through the GLP-1 receptor, with minimal GIP receptor contribution at therapeutic doses.

Research on tirzepatide using mice may not fully reflect how it works in humans, as mice require much higher doses for GIP receptor activation. This highlights the importance of human-specific studies for understanding the drug's full mechanism.

Treatment with GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) is associated with a significantly increased risk of developing psychiatric disorders, including major depression, anxiety, and suicidal behavior, in patients with obesity.

If you are taking or considering GLP-1 medications like Ozempic or Wegovy for obesity, be aware that studies link these drugs to a higher risk of depression, anxiety, and suicidal thoughts, especially with long-term use. Discuss your mental health history with your doctor before starting, and monitor your mood closely. If you experience worsening depression or suicidal thoughts, contact your healthcare provider immediately.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with increased subclinical atherosclerosis (measured by carotid intima-media thickness and coronary artery calcification) and incident cardiovascular events, but does not independently increase cardiovascular mortality risk after adjusting for confounders.

If you have MASLD, prioritize cardiovascular risk management (blood pressure, lipids, glucose) as aggressively as you manage your liver health. Your risk of heart events is elevated, but your risk of dying from liver failure is lower than dying from heart disease. Comprehensive cardiometabolic risk management is warranted.

Enteroendocrine cells (EECs) regulate the gut-brain axis through two distinct mechanisms: slow endocrine hormone release into the bloodstream and rapid synaptic signaling via neuropod cells.

Your gut has a direct 'phone line' to your brain. Foods trigger specific cells (EECs) that send signals either slowly through hormones or instantly through nerves. This is why drugs like semaglutide (Ozempic) work—they amplify these natural signals to regulate hunger and blood sugar. Understanding this helps explain why gut health directly impacts mood and metabolism.

Neuropod cells communicate nutrient information to the vagus nerve primarily via glutamate release, allowing for rapid distinction between sugar and artificial sweeteners.

Your gut has a specific 'sugar detector' (neuropod cells) that sends a fast signal to your brain using glutamate. This signal is triggered by real sugar (sucrose) but not by artificial sweeteners. This might explain why artificial sweeteners don't always satisfy sugar cravings or trigger the same metabolic responses as real sugar.

Serotonin (5-HT) released from enterochromaffin (EC) cells modulates visceral sensitivity and pain signaling via direct synaptic interaction with nociceptive neurons.

If you have IBS or chronic gut pain, your gut cells (EC cells) might be sending too many pain signals to your brain using serotonin. Blocking these signals (with specific antagonists) can reduce pain and anxiety, showing that gut pain is a neurological issue, not just inflammation.

Tirzepatide treatment is not significantly associated with an increased risk of pancreatitis compared to control groups (placebo, basal insulin, or GLP-1 RAs) in patients with type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity and are considering Tirzepatide, current data from multiple clinical trials suggests it does not significantly increase your risk of pancreatitis compared to other common diabetes or weight-loss medications. This is reassuring news if you were avoiding the drug due to fears of pancreatic inflammation.